Fusion Pharmaceuticals Inc.

NasdaqGS:FUSN 株式レポート

時価総額:US$1.8b

Fusion Pharmaceuticals マネジメント

マネジメント 基準チェック /44

Fusion Pharmaceuticalsの CEO はJohn Valliantで、 Dec2014年に任命され、 の在任期間は 9.5年です。 の年間総報酬は$ 2.08Mで、 28.7%給与と71.3%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.37%を直接所有しており、その価値は$ 6.86M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と5.2年です。

主要情報

John Valliant

最高経営責任者

US$2.1m

報酬総額

CEO給与比率28.7%
CEO在任期間9.5yrs
CEOの所有権0.4%
経営陣の平均在職期間2.8yrs
取締役会の平均在任期間5.2yrs

経営陣の近況

Recent updates

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Mar 03

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30
Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10
Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Aug 09

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Jun 23

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Fusion Pharma trades higher on early-stage data for cancer therapy

Jun 14

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01
How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25
Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Fusion Pharmaceuticals EPS misses by $0.04

Nov 10

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Nov 02

CEO報酬分析

Fusion Pharmaceuticals の収益と比較して、John Valliant の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$2mUS$597k

-US$95m

Sep 30 2023n/an/a

-US$91m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$92m

Dec 31 2022US$3mUS$595k

-US$88m

Sep 30 2022n/an/a

-US$80m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$3mUS$597k

-US$81m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$86m

Dec 31 2020US$7mUS$505k

-US$80m

Sep 30 2020n/an/a

-US$75m

Jun 30 2020n/an/a

-US$65m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$1mUS$399k

-US$16m

報酬と市場: Johnの 総報酬 ($USD 2.08M ) は、 US市場 ($USD 5.27M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Johnの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

John Valliant (53 yo)

9.5yrs

在職期間

US$2,081,586

報酬

Dr. John F. Valliant Ph D, is Founder of Fusion Pharmaceuticals Inc. and its Chief Executive Officer & Director since December 2014. He served as Member of Scientific Advisory Board of Molecular Insight Ph...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Valliant
Founder9.5yrsUS$2.08m0.37%
$ 6.9m
Mohit Rawat
President & Chief Business Officer2.8yrsUS$1.41m0.015%
$ 276.8k
John Crowley
CFO & Compliance Officer5.3yrsUS$1.30m0.012%
$ 224.4k
Eric Burak
Chief Technology Officer2.6yrsUS$1.42m0.045%
$ 829.5k
Christopher Leamon
Chief Scientific Officer2.6yrsデータなし0.014%
$ 257.7k
Amanda Cray
Senior Director of Investor Relations & Corporate Communicationsno dataデータなしデータなし
Maria Stahl
Chief Legal Officer3.8yrsデータなしデータなし
Eric Hoffman
Senior Vice President of Business Development2.8yrsデータなしデータなし
Cara Ferreira
Chief of Staffno dataデータなしデータなし
Joanne Schindler
Executive Vice President of Medical Director & Clinical Development2.2yrsデータなしデータなし
Dmitri Bobilev
Chief Medical Officer1.6yrsデータなしデータなし

2.8yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: FUSNの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
John Valliant
Founder9.5yrsUS$2.08m0.37%
$ 6.9m
Barbara Duncan
Independent Chairperson of the Board3.7yrsUS$126.49k0%
$ 0
Pablo Cagnoni
Independent Director4.5yrsUS$103.49k0%
$ 0
Steven Gannon
Independent Director4.4yrsUS$108.24k0.066%
$ 1.2m
Jeremy Bender
Independent Directorless than a yearUS$101.89k0%
$ 0
Deepak Khuntia
Member of Advisory Board5.9yrsデータなしデータなし
Donald Bergstrom
Independent Director3.2yrsUS$98.49k0%
$ 0
Geoffrey Shapiro
Member of Advisory Board5.9yrsデータなしデータなし
Rosalyn Juergens
Member of Advisory Board5.9yrsデータなしデータなし
Gillies O'Bryan-Tear
Member of Advisory Board5.9yrsデータなしデータなし
Oliver Sartor
Member of Advisory Board5.9yrsデータなしデータなし
Philina Lee
Independent Director3.3yrsUS$97.49k0%
$ 0

5.2yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: FUSNの 取締役会経験豊富 であると考えられます ( 5.2年の平均在任期間)。